Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Compass Therapeutics and Akebia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -49.93% | -43.76% |
| Akebia Therapeutics | -22.60% | -156.59% | -11.53% |
Valuation & Earnings
This table compares Compass Therapeutics and Akebia Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | N/A | N/A | -$66.49 million | ($0.47) | -1.46 |
| Akebia Therapeutics | $236.20 million | 0.45 | -$5.34 million | ($0.16) | -2.41 |
Akebia Therapeutics has higher revenue and earnings than Compass Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Compass Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Compass Therapeutics and Akebia Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Compass Therapeutics presently has a consensus target price of $9.99, suggesting a potential upside of 1,360.77%. Akebia Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 807.91%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than Akebia Therapeutics.
Insider and Institutional Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Compass Therapeutics beats Akebia Therapeutics on 10 of the 14 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
